Syndax announced the beginning of its Phase 2 study of entinostat in combination with anastrozole in postmenopausal women with operable triple-negative breast cancer to evaluate biomarkers and surrogates for response. This multicenter study will investigate whether patient tumors can be reprogrammed to express estrogen receptors, hence rendering them to be sensitive to hormonal agents.

Entinostat is an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor with a long half-life that allows for weekly or every-other-week dosing. HDAC inhibitors modify the DNA structure of tumor cells to cause their differentiation and programmed cell death (apoptosis) and are therefore considered to offer a mechanism of action that has the particular potential to halt tumor progression and induce tumor regression.

For more information call (781) 419-1400 or visit www.syndax.com